tauroursodeoxycholic acid (TUDCA)

DRUG4 trials

Sponsors

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Robin Goland, MD, Fudan University, Peking University First Hospital

Conditions

Amyotrophic Lateral SclerosisHepatocellular Carcinoma (HCC)Metabolic Dysfunction-Associated Steatotic Liver Disease Infant DevelopmentType 1 Diabetes

Phase 2

Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

CompletedNCT00877604

Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAmyotrophic Lateral Sclerosis

Start: 2008-06-30End: 2012-04-30Updated: 2014-11-26

Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

CompletedNCT02218619

Robin Goland, MDType 1 Diabetes

Start: 2015-08-31End: 2019-12-31Updated: 2025-06-05

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

RecruitingNCT07100392

Fudan UniversityHepatocellular Carcinoma (HCC)

Start: 2025-08-14End: 2028-08-01Target: 141Updated: 2025-08-17

TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index

Not yet recruitingNCT07517276

Peking University First HospitalMetabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

Start: 2026-04-02End: 2026-07-30Target: 80Updated: 2026-04-08